SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...

At a time when charitable giving is down, a group of Dallas teens is turning to music to raise funds for the battle against ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Recent studies show that HIV patients are 10 to 20 times more likely to develop lymphoma compared to individuals without HIV.

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...